Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Screening for Chemosensitizers from Natural Plant Extracts through the Inhibition Mechanism of P-glycoprotein

  • Ahn, Hee-Jeong (Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine) ;
  • Song, Im-Sook (Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine)
  • Received : 2010.07.14
  • Accepted : 2010.10.05
  • Published : 2010.10.20
Download PDF
⟨ Previous Next ⟩

Abstract

P-gp plays a critical role in drug disposition and represents a mechanism for the development of multidrug resistance. Flavonoids, a major class of natural compounds widely present in foods and herbal products, have been shown to inhibit P-gp. Therefore, the aim of this study was to identify new candidate chemosensitizers by screening various plant extracts. The ability of natural plant extracts to inhibit P-gp activity was assessed by measuring cellular accumulation of calcein AM, daunorubicin and vincristine in P-gp overexpressing MDCKII-MDR1 cells. Among more than 800 plant extracts, eight were found to inhibit P-gp activity. Curcuma aromatica extract produced greatest inhibition, followed by Curcuma longa and Dalbergia odorifera extracts. Extracts of Aloe ferox, Curcuma zedoariae rhizome, Zanthoxylum planispinum, and Ageratum conyzoides showed moderate inhibitory effects. Curcumin and quercetin exhibited similar inhibition of P-gpmediated efflux of daunorubicin and vincristine, and flavones had a lesser effect. When chemosensitizing effect was evaluated by measuring daunorubicin sensitivity to MDCKII-MDR1 cells in the presence of natural plant extracts, Curcuma aromatica showed the most potent chemosensitizing effect based on daunorubicin cytotoxicity. In conclusion, natural plant extracts such as Curcuma aromatica can potently inhibit P-gp activity and may have potential as a novel chemosensitizers.

Keywords

References

  1. Ahn, H.J., Kim, J.Y., Lee, C.H., Song, I.S., Liu, K.H., 2008.Screening of chemosensitizer candidates using natural extracts. J. Life Sci. 18, 1244-1248. https://doi.org/10.5352/JLS.2008.18.9.1244
  2. Bailey, D.G., Spence, J.D., Munoz, C., Arnold, J.M., 1991. Interaction of citrus juices with felodipine and nifedipine. Lancet 337, 268-269. https://doi.org/10.1016/0140-6736(91)90872-M
  3. Bansal, T., Jaggi, M., Khar, R.K., Talegaonkar, S., 2009. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J. Pharm. Pharm. Sci. 12, 46-78. https://doi.org/10.18433/J3RC77
  4. Choi, C.H., 2005. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5, 30. https://doi.org/10.1186/1475-2867-5-30
  5. Choi, J.S., Choi, H.K., Shin, S.C., 2004a. Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int. J. Pharm. 275, 165-170. https://doi.org/10.1016/j.ijpharm.2004.01.032
  6. Choi, J.S., Jo, B.W., Kim, Y.C., 2004b. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur. J. Pharm. Biopharm. 57, 313-318. https://doi.org/10.1016/j.ejpb.2003.11.002
  7. Dantzig, A.H., de Alwis, D.P., Burgess, M., 2003. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55, 133-150. https://doi.org/10.1016/S0169-409X(02)00175-8
  8. Deferme, S., Augustijns, P., 2003. The effect of food components on the absorption of P-gp substrates: a review. J. Pharm. Pharmacol. 55, 153-162. https://doi.org/10.1211/002235702603
  9. Deferme, S., Van Gelder, J., Augustijns, P., 2002. Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an invitro screening. J. Pharm. Pharmacol. 54, 1213-1219. https://doi.org/10.1211/002235702320402053
  10. Deng, S.G., Wu, Z.F., Li, W.Y., Yang, Z.G., Chang, G., Meng, F.Z., Mo, L.L., 2004. Safety of Curcuma aromatica oil gelatin microspheres administered via hepatic artery. World J. Gastroenterol. 10, 2637-2642. https://doi.org/10.3748/wjg.v10.i18.2637
  11. Efferth, T., Davey, M., Olbrich, A., Rucker, G., Gebhart, E., Davey, R., 2002. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug- resistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis. 28, 160-168. https://doi.org/10.1006/bcmd.2002.0492
  12. Essodaigui, M., Broxterman, H.J., Garnier-Suillerot, A., 1998. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37, 2243-2250. https://doi.org/10.1021/bi9718043
  13. Fawole, O.A., Amoo, S.O., Ndhlala, A.R., Light, M.E., Finnie, J. F., Van Staden, J., 2010. Anti-inflammatory, anticholinesterase, antioxidant and phytochemical properties of medicinal plants used for pain-related ailments in South Africa. J. Ethnopharmacol. 127, 235-241. https://doi.org/10.1016/j.jep.2009.11.015
  14. Havsteen, B.H., 2002. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96, 67-202. https://doi.org/10.1016/S0163-7258(02)00298-X
  15. Krishna, R., Mayer, L.D., 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283. https://doi.org/10.1016/S0928-0987(00)00114-7
  16. Lee, J.S., Kim, D.H., Liu, K.H., Oh, T.K., Lee, C.H., 2005. Identification of flavonoids using liquid chromatography with electrospray ionization and ion trap tandem mass spectrometry with an MS/MS library. Rapid Commun. Mass Spectrom. 19, 3539-3548. https://doi.org/10.1002/rcm.2230
  17. Li, Y., Wo, J.M., Liu, Q., Li, X., Martin, R.C., 2009. Chemoprotective effects of Curcuma aromatica on esophageal carcinogenesis. Ann. Surg. Oncol., 16 515-523. https://doi.org/10.1245/s10434-008-0228-0
  18. Limtrakul, P., 2007. Curcumin as chemosensitizer. Adv. Exp. Med. Biol. 595, 269-300. https://doi.org/10.1007/978-0-387-46401-5_12
  19. Liow, J.S., Lu, S., McCarron, J.A., Hong, J., Musachio, J.L., Pike, V.W., Innis, R.B., Zoghbi, S.S., 2007. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)- (-)-RWAY. Synapse 61, 96-105. https://doi.org/10.1002/syn.20348
  20. Liscovitch, M., Lavie, Y., 2002. Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5, 349-355.
  21. Marchetti, S., Mazzanti, R., Beijnen, J.H., Schellens, J.H., 2007. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 12, 927-941. https://doi.org/10.1634/theoncologist.12-8-927
  22. Muzi, M., Mankoff, D.A., Link, J.M., Shoner, S., Collier, A.C., Sasongko, L., Unadkat, J.D., 2009. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 50, 1267- 1275. https://doi.org/10.2967/jnumed.108.059162
  23. Ozben, T., 2006. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580, 2903-2909. https://doi.org/10.1016/j.febslet.2006.02.020
  24. Pilarski, L.M., Yatscoff, R.W., Murphy, G.F., Belch, A.R., 1998. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers. Leukemia 12, 505-509. https://doi.org/10.1038/sj.leu.2400984
  25. Renes, J., de Vries, E.G., Nienhuis, E.F., Jansen, P.L., Muller, M., 1999. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br. J. Pharmacol. 126, 681-688. https://doi.org/10.1038/sj.bjp.0702360
  26. Shin, S.C., Choi, J.S., Li, X., 2006. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int. J. Pharm. 313, 144-149. https://doi.org/10.1016/j.ijpharm.2006.01.028
  27. Tan, B., Piwnica-Worms, D., Ratner, L., 2000. Multidrug resistance transporters and modulation. Curr. Opin. Oncol. 12, 450-458. https://doi.org/10.1097/00001622-200009000-00011
  28. Thomas, H., Coley, H.M., 2003. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165. https://doi.org/10.1177/107327480301000207
  29. Versantvoort, C.H., Broxterman, H.J., Lankelma, J., Feller, N., Pinedo, H.M., 1994. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 48, 1129-1136. https://doi.org/10.1016/0006-2952(94)90149-X
  30. Wu, W.Y., Xu, Q., Shi, L.C., Zhang, W.B., 2000. Inhibitory effects of Curcuma aromatica oil on proliferation of hepatoma in mice. World J. Gastroenterol. 6, 216-219.
  31. Zhang, S., Yang, X., Morris, M.E., 2004. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol. Pharmacol. 65, 1208-1216. https://doi.org/10.1124/mol.65.5.1208
  32. Zhou, S., Lim, L.Y., Chowbay, B., 2004. Herbal modulation of Pglycoprotein. Drug Metab. Rev. 36, 57-104. https://doi.org/10.1081/DMR-120028427